OPTIMISE
Research type
Research Study
Full title
Optimising Psoriatic Arthritis Therapy with Immunological Methods to Increase Standard Evaluation
IRAS ID
287528
Contact name
Laura Coates
Contact email
Sponsor organisation
University of Oxford, Clinical Trials and Research Governance
ISRCTN Number
ISRCTN17228602
Duration of Study in the UK
2 years, 6 months, 28 days
Research summary
Our aim is to test whether we can predict if people with psoriatic arthritis (PsA) will respond to certain biologic drugs using blood tests. We will test if high levels of a type of T cells (activated Th17 cells) or other laboratory tests predict response. We will use statistical tests to estimate how effective these approaches would be for each individual. If successful, this approach could ensure that patients receive their best option first, ensuring their disease is controlled and quality of life improved, while avoiding unnecessary drug use. This is likely to save money for the NHS
PsA is an inflammatory arthritis that develops in around 15% of people with psoriasis, causing swollen and painful joints. For patients who do not respond to standard arthritis drugs, two classes of biologic drugs are available (TNF or IL-17 blockers). A similar proportion of patients respond to both with around 50% achieving a good response. However, we do not know how to predict which patient will respond best to each drug.
Patients with PsA about to start their first biologic will be invited to join the study. They will have a blood sample taken to measure their activated Th17 cells. The patients will be allocated to receive either TNF or IL-17 blocking biologics. We will measure how well they respond after 6 months treatment and test whether the initial blood test result could have predicted their response.REC name
North West - Preston Research Ethics Committee
REC reference
21/NW/0016
Date of REC Opinion
24 Feb 2021
REC opinion
Further Information Favourable Opinion